Search

Search Constraints

You searched for: Author/Creator Brioli, Annamaria

Search Results

1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

2. Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Issue 9 (September 2013)

3. Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Issue 7 (July 2015)

5. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Issue 9 (1st September 2016)

6. Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high‐dose therapy. (29th January 2013)

8. Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia. (25th April 2022)

10. The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. Issue 11 (November 2014)